Buchumschlag

Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition

M William Audeh Division of Medical Oncology, Samuel Oschin Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA Abstract: Inhibitors of the poly(adenosine triphosphate-ribose) polymerase (PARP)-1 enzyme induce synthetic lethality in cancers with ineffective DNA (DNA) repair or homolo...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
1. Verfasser:	Audeh MW (VerfasserIn)
Format:	Buch
Veröffentlicht:	Dove Medical Press, 2014-10-01T00:00:00Z.
Schlagworte:	article
Online-Zugang:	Connect to this object online.
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Expression of poly(Adenosine Diphosphate-Ribose) polymerase protein in breast cancer
von: Akanksha, et al.
Veröffentlicht: (2022)

Asthma and poly(ADP-ribose) polymerase inhibition: a new therapeutic approach
von: Zaffini R, et al.
Veröffentlicht: (2018)

Poly(ADP-ribose) polymerase (PARP) inhibitors and ovarian cancer
von: Chia-Hao Liu, et al.
Veröffentlicht: (2017)

Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy
von: Stephen A. Jannetti, et al.
Veröffentlicht: (2020)

The Role of Poly(ADP-ribose) Polymerase-1 in Rheumatoid Arthritis
von: Samuel García, et al.
Veröffentlicht: (2015)

Cytochrome P450 inhibitor/inducer treatment patterns among patients in the United States with advanced ovarian cancer who were prescribed or were eligible for poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors in the first-line maintenance setting
von: Bobbie J. Rimel, et al.
Veröffentlicht: (2024)

Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancer
von: Ruihong Dong, et al.
Veröffentlicht: (2023)

Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond
von: Stergios Boussios, et al.
Veröffentlicht: (2020)

Poly (ADP-Ribose) Polymerase Mediates Diabetes-Induced Retinal Neuropathy
von: Ghulam Mohammad, et al.
Veröffentlicht: (2013)

Potential biological role of poly (ADP-ribose) polymerase (PARP) in male gametes
von: Sarkar Oli, et al.
Veröffentlicht: (2009)

Targeted therapy with Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of solid tumours
von: Faustyna Piędel, et al.
Veröffentlicht: (2020)

Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations
von: Qin Xu, et al.
Veröffentlicht: (2021)

Identification of probe-quality degraders for Poly(ADP-ribose) polymerase-1 (PARP-1)
von: Zhimin Zhang, et al.
Veröffentlicht: (2020)

Inhibition of poly(ADP-ribose)polymerase contributes to the reduction of oxidative stress in murine liver under the conditions of experimental endotoxemia
von: N. H. Hrushka, et al.
Veröffentlicht: (2019)

Regulation of HIV-1 replication by Poly (ADP-ribose) polymerase-1 in CD4 T cells.
von: M. Llano, et al.
Veröffentlicht: (2017)

Decreasing Poly(ADP-ribose) Polymerase activity restores ΔF508 CFTR trafficking
von: Suzana Maria Anjos, et al.
Veröffentlicht: (2012)

Cost-Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Cancer Treatment: A Systematic Review
von: Vivien Kin Yi Chan, et al.
Veröffentlicht: (2022)

Roles of poly(ADP-ribose) polymerase 1 and mitophagy in progeroid syndromes as well as physiological ageing
von: Naoko Suga, et al.
Veröffentlicht: (2023)

Dose Adjustment of Poly (ADP‑Ribose) Polymerase Inhibitors in Patients with Hepatic or Renal Impairment
von: Zhao D, et al.
Veröffentlicht: (2022)

Poly ADP-ribose polymerase (PARP) inhibitors - new therapeutic strategies in Acute Myeloid Leukemia: a literature review
von: Emilia Nowicka, et al.
Veröffentlicht: (2022)

Selective Sparing of Striatal Interneurons after Poly (ADP-Ribose) Polymerase 1 Inhibition in the R6/2 Mouse Model of Huntington's Disease
von: Emanuela Paldino, et al.
Veröffentlicht: (2017)

24 Correlation of clinical outcomes and poly ADP ribose polymerase activity in high grade serous ovarian cancer
von: Elaine T. Fleming, et al.
Veröffentlicht: (2023)

Poly (ADP-Ribose) Polymerase inhibitors (PARPi) therapy response in an acral melanoma patient with EMSY gene amplification
von: George Nassief, BA, et al.
Veröffentlicht: (2024)

1-Oxo-3,4-dihydroisoquinoline-4-carboxamides as novel druglike inhibitors of poly(ADP-ribose) polymerase (PARP) with favourable ADME characteristics
von: Alexander Safrygin, et al.
Veröffentlicht: (2021)

Small interfering RNA mediated Poly (ADP-ribose) Polymerase-1 inhibition upregulates the heat shock response in a murine fibroblast cell line
von: Zingarelli Basilia, et al.
Veröffentlicht: (2011)

Current status and future promise of next-generation poly (ADP-Ribose) polymerase 1-selective inhibitor AZD5305
von: Jingcao Zheng, et al.
Veröffentlicht: (2023)

Poly (ADP-Ribose) Polymerase 1 Mediated Arginase II Activation Is Responsible for Oxidized LDL-Induced Endothelial Dysfunction
von: Qi Wang, et al.
Veröffentlicht: (2018)

Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors in Diabetic Retinopathy: An Attractive but Elusive Choice for Drug Development
von: Etelka Pöstyéni, et al.
Veröffentlicht: (2024)

RESIDUAL PLATELET REACTIVITY DURING THERAPY WITH INHIBITORS OF CYCLOOXIGENASE OR ADENOSINE DIPHOSPHATE RECEPTORS
von: A. A. Lomonosova, et al.
Veröffentlicht: (2015)

RESIDUAL PLATELET REACTIVITY DURING THERAPY WITH INHIBITORS OF CYCLOOXIGENASE OR ADENOSINE DIPHOSPHATE RECEPTORS
von: A. A. Lomonosova, et al.
Veröffentlicht: (2015)

Angiosarcoma of the ovary treated with polyadenosine ribose polymerase Inhibition, a case report and review of the literature
von: Andrea M. Johnson, et al.
Veröffentlicht: (2023)

Involvement of poly(ADP-ribose) polymerase-1 in development of spinal cord injury in Chinese individuals: a Chinese clinical study
von: Meng Q, et al.
Veröffentlicht: (2017)

Cost comparison of adverse event management among breast and ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors: analysis based on phase 3 clinical trials
von: Lin Fan, et al.
Veröffentlicht: (2022)

Role of flavonoids in inhibiting triple-negative breast cancer
von: Shuai Wang, et al.
Veröffentlicht: (2024)

First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of a Neuroprotective Poly (ADP‐ribose) Polymerase‐1 Inhibitor, JPI-289, in Healthy Volunteers
von: Han S, et al.
Veröffentlicht: (2020)

Besides the front-line maintenance therapy, is any positive impact of poly (ADP-ribose) polymerase (PARP) inhibitors on recurrent high-grade ovarian cancer?
von: Yiu-Tai Li, et al.
Veröffentlicht: (2024)

Garmultin-A Incites Apoptosis in CB3 Cells Through miR-17-5p by Attenuating Poly (ADP-Ribose) Polymerase-1
von: Jianfei Qiu, et al.
Veröffentlicht: (2022)

Risk of selected gastrointestinal toxicities associated with poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer: a meta-analysis of published trials
von: Liu Y, et al.
Veröffentlicht: (2018)

Design, synthesis, and biological evaluation of quinazolin-4(3H)-one derivatives co-targeting poly(ADP-ribose) polymerase-1 and bromodomain containing protein 4 for breast cancer therapy
von: Xiaosa Chang, et al.
Veröffentlicht: (2021)

Three-component Castagnoli-Cushman reaction with ammonium acetate delivers 2-unsubstituted isoquinol-1-ones as potent inhibitors of poly(ADP-ribose) polymerase (PARP)
von: Alexander Safrygin, et al.
Veröffentlicht: (2021)